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Degradation of extracellular matrix (ECM) is one of the first steps in
tumor invasion and metastasis. Matrix metalloproteinases (MMP)
have been strongly implicated in this step. Membrane-type MMP-1
(MT1-MMP) was first identified as an activator of proMMP-2 expressed
on the surface of tumor cells and later, not only ECM macromolecules
but also various biologically important molecules, were shown to
serve as substrates for MT1-MMP. Accumulated lines of evidence have
demonstrated that MT1-MMP expression level is closely associated
with invasiveness and malignancy of tumors, suggesting that MT1-
MMP is one of the most critical factors for tumor invasion and
metastasis. Despite enthusiasm for MMP inhibitors, phase III trials have
not yet demonstrated significance in overall survival and side-effects
remain an issue. An understanding of the functions of MT1-MMP
could supply clues for developing novel therapeutic strategies
targeting MT1-MMP. (Cancer Sci 2005; 96: 212–217)
Extracellular matrix (ECM) macromolecules are importantfor creating the cellular environments required during develop-
ment and morphogenesis. Matrix metalloproteinases (MMP)
play important roles in development and morphogenesis by
participating in ECM re-modeling.(1–3) Under normal physiological
conditions, the activities of MMP are precisely regulated at the
level of transcription, activation of the precursor zymogens,
interaction with specific ECM components, and inhibition by
endogenous inhibitors.(4) Cancer cells also make use of MMP
for invasion and metastasis. The invading cells are forced to
proliferate within an embedded dense three-dimensional matrix
composed largely of type I collagen or cross-linked fibrin.
Membrane type MMP-1 (MT1-MMP) has been thought to play
a major role in this step.(5,6)
Unique structure of MT1-MMP. Currently 23 MMP have been
identified in humans and they are divided into two groups;
secretory and membrane-type (Fig. 1).(7) While MT1-MMP has
a common MMP domain structure with pre-, pro-, catalytic and
hemopexin-like domains, it also has unique insertions. First there
is an insertion of 11 amino-acids between the pro-peptide and
the catalytic domains, which contains the recognition sequence
for the Golgi-associated processing enzyme furin. Another unique
insertion at the C-terminus contains a hydrophobic amino-acid
sequence that acts as a transmembrane domain. Thus, unlike
secretory MMP, MT1-MMP is expressed on the cell surface in
an active form.(5)
Implication of MT1-MMP in tumor invasion and metastasis. MMP-2
has been suspected to be associated with tumor invasion because
it can degrade the type IV collagen, which is a major component
of the basement membrane. An active form of MMP-2 has
frequently been detected in tumor tissues.(8,9) The expression of
MT1-MMP has been demonstrated in tumor tissues, in which
MMP-2 is always activated.(5,10–12) Furthermore, the MMP-2
activation ratio correlates with the MT1-MMP expression level,
suggesting that MT1-MMP is the MMP-2 activator in tumor
tissues. An analysis of MT1-MMP-deficient mice, which had
severe defects in bone formation and died within a few weeks of
birth, clearly showed that MT1-MMP is the major activator of
MMP-2 during tissue morphogenesis.(13) Interestingly MMP-2-
deficient mice do not show such severe defects, indicating that
MT1-MMP has critical functions in addition to MMP-2 activation.
ECM macromolecules including type I collagen and various
biologically important molecules are now known to serve as
substrates for MT1-MMP, which will be discussed in the following
sections (Table 1).(14–23)
Induction of MT1-MMP expression by transformation of epithelial
cells. MT1-MMP is associated with not only tumor invasion and
metastasis but also tissue morphogenesis, which is clearly demon-
strated in vitro by the Madin-Darby canine kidney (MDCK)
epithelial cell system (Fig. 2). MDCK cells are kidney-derived
normal epithelial cells that show typical cobblestone morphology
when cultured in a plastic dish. MDCK cells form cysts when
cultured in three-dimensional type I collagen gel, and grow to
form branching tubules in the presence of hepatocyte growth
factor.(24) MT1-MMP expression is induced at a low level in
tube-forming MDCK cells. Collagenolytic activity of MT1-MMP
plays an essential role in tube formation in three-dimensional
collagen gel.(25) Oncogenic transformation of MDCK cells by
v-src or erbB2 induces loss of cell-to-cell adhesion and a high-
level expression of MT1-MMP.(26) Transformed cells acquire the
capacity to invade collagen gels, tumorigenicity and metastatic
ability in nude mice. Inhibition of invasive growth of trans-
formed cells in collagen gel by MMP inhibitors indicates that
MT1-MMP plays a major role in their invasive growth.
MT1-MMP and extra-cellular signal-regulated kinase activation.
Collagen matrix acts as physical barrier for tumor-cell invasion, but
at the same time it provides cells with various signals for growth,
survival, differentiation, migration and so on. Extra-cellular signal-
regulated kinase (ERK) is activated in cells cultured in type I
collagen matrix or on collagen sheet through interaction with
integrins. ERK activated by collagen culture of cells in turn
stimulates MT1-MMP expression (Fig. 3a).(27) MT1-MMP thus
induced by ERK plays an essential role in sustained activation
of ERK. Activation of ERK is not maintained in the presence of
MT1-MMP inhibitor. Thus, MT1-MMP functions in a positive
feedback loop to induce sustained ERK activation and subsequent
MT1-MMP accumulation, which collectively promotes cell migra-
tion on collagen (Fig. 3b).
Decorin and lumican as substrates for MT1-MMP. ECM regulates
cell growth/survival and differentiation, which vary between
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tissues. Some ECM components such as decorin and lumican,
both of which belong to a small lecine-rich proteoglycan family,
negatively regulate cell growth and are classified as tumor
suppressors.(28,29) Both docorin and lumican have been shown to
induce p21/Waf-1, an inhibitor of cyclin-dependent kinases in
tumor cells that down-regulates cell growth and tumorigenicity
(Fig. 4).(16) MT1-MMP expressed on the surface of tumor cells
degrades decorin and lumican, which restores tumorigenicity.(16)
Lumican is the most abundant proteoglycan among small lecine-
rich proteoglycan family members in breast cancer.(30) Although
lumican mRNA expression is high within the tumor and tumor
margin, lumican protein is not immunolocalized within the tumor
but within the collagenous stroma. As MT1-MMP is predominantly
found within breast cancer tumors,(5,12) lumican protein expressed
by tumor cells would be degraded by MT1-MMP. This may
account for the observation that differences between lumican
levels in normal and malignant breast tissues observed by both
immunohistochemistry and Western blot are not as marked as
those seen at the level of mRNA expression.(30)
Cd44. CD44 is a major receptor for hyaluronan and its
association with tumor malignancy has been investigated for a
long time. Furthermore, recent evidence indicates the importance
of CD44 cleavage in tumor invasion and metastasis. Cleavage
of CD44 by MT1-MMP has been demonstrated with in vitro
experiments,(19) and the analysis of cleaved fragments of CD44
in human tumor tissues indicated the involvement of MT1-
MMP.(31) CD44 is also cleaved by structurally related ADAM
metalloproteinases (ADAM: a disintegrin and metalloproteinase).
The mechanism and significance of CD44 cleavage were reviewed
by Nagano and Saya.(32)
Syndecan-1. Another interesting cell-surface receptor cleaved
by MT1-MMP is syndecan-1. Syndecans are transmembrane
heparan sulfate proteoglycans expressed on all adherent cells,
and have been proposed to play important roles in tissue
morphogenesis by virtue of their ability to bind, through their
covalently attached glycosaminoglycan chains, to a variety of
ECM molecules including fibronectin, thrombospondin, various
collagens, and heparin-binding growth-associated molecules and
growth factors, such as basic fibroblast growth factor. As the
expression of syndecans appears to be controlled during both
development and the progression of tumor cells to the metastatic
phenotype, it has been proposed that syndecans are important
regulators of the migratory and invasive behaviors of both
normal and transformed cells.(33,34) Syndecan-1 is abundant in
normal epithelial cells and tissues, localizing to both basal and
suprabasal cell layers. Disruption of syndecan-1 expression in
Fig. 1. Domain structure of matrix metallopro-
teinases (MMP). The domain organization of MMP
is as indicated: Sig, signal peptide; Pro, pro-peptide;
Cat(Zn2+), catalytic; Pex, hemopexin-like; Tm/Cyt,
transmembrane and cytoplasmic. RRKR is the re-
cognition sequence for furin.
Table 1. Substrates for MT1-MMP and cleavage sequences
 
Protein Cleavage sequences* Reference
ECM Components
Type I Collagen α1(I) Chain 771PGPQG↓IAGQR 14
Type I Collagen α2(I) Chain 771PGPQG↓LLGAPG↓ILGLP 14












Syndecan 1 78PEPTG↓LEATA 20
241GASQG↓LLDRK
Ligands and Others
KiSS 1 114WNSFG↓LRFGK 21
Interleukin 8 23AVLPR↓SAKEL 22
Secretory Leukocyte Protease Inhibitor 20WAVEG↓SGKSF 22
Pro Tumor Necrosis Factor α 65RDLSL↓ISP↓LA↓QA↓VRSSS 22
Connective Tissue Growth Factor 177PALAA↓YRLEDTF 22
Amyloid Precursor Protein 575DVLAN↓MISEP 23
MT1-MMP, membrane type matrix metalloproteinases-1; ECM, extracellular matrix. *MT1-
MMP cleavage sites are indicated by the arrow.
214 © Japanese Cancer Association doi: 10.1111/j.1349-7006.2005.00039.x
cultured cells leads to an epithelial mesenchymal transformation,
with associated changes in cell polarity, cell-cell adhesion and
altered epithelial-specific gene expression.(35,36) Syndecan-1 is
cleaved by MT1-MMP at a juxtamembrane site, which results in
shedding of its ectodomain and stimulates cell migration.(20)
Syndecan-1 shedding is also mediated by MMP-7/matrilysin.(37)
High cancer cell syndecan-1 expression in tissue biopsies has
been found to be associated with a favorable outcome. Low
syndecan-1 expression in immunostaining of cancer tissues is
associated with a poor histological grade of differentiation in
various cancer tissues. High serum syndecan-1 levels at diagnosis
were reported to be associated with poor outcome in lung cancer.(38)
It should be hypothesized that syndecan-1 ectodomain might
be shed by MT1-MMP and/or MMP-7 expressed in tumor cells,
because expression levels of MT1-MMP and MMP-7 are also
associated with the malignancy of tumors including lung cancer.(12)
KiSS-1/Metastin. The KiSS-1 gene was identified originally as
being differentially up-regulated in C8161 melanoma cells that
have lost the potential to metastasize after microcell-mediated
transfer of human chromosome 6.(39,40) A C-terminally amidated
peptide with 54 amino acid residues corresponding to residues
68–121 of the full-length KiSS-1 protein was isolated from
human placenta as the endogenous ligand of an orphan G-protein-
coupled receptor (hOT7T175/AXOR12/human GPR54), and
was named metastin, because it suppressed metastasis of B16-
BL6 melanoma cells expressing hOT7T175.(41) Metastin peptide
is cleaved by various MMP including MT1-MMP.(21) Metastin
down-regulates migration of receptor-expressing tumor cells and
cleavage of metastin by MT1-MMP inactivates its ligand activity.
Thus, cleavage of metastin by MT1-MMP abrogates metastin-
mediated inhibition of tumor metastasis.
Conclusion
A recent new idea indicates the importance of the physical three-
dimensionality of the matrix in regulating normal cell behavior,
including cell proliferation and Hotary et al. emphasized the
contribution of MT1-MMP in tumor cell growth in a three-
dimensional matrix composed largely of type I collagen or
crosslinked fibrin.(6) Various substrates for MT1-MMP other
Fig. 2. Induction of membrane type matrix metalloproteinases-1 (MT1-MMP). A: Madin-Darby canine kidney (MDCK) cells cultured on plastic dish
show a normal epithelial morphology (a), and loose cell-cell adhesion by transformation with erbB2 gene (b). MDCK cells form cysts in type I
collagen gel (c), and erbB2-transformed cells show invasive growth in it (d). Addition of hepatocyte growth factor to the collagen-gel culture of
MDCK cells induces formation of branching tubules (e). Addition of MMP-specific inhibitor BB94 to the collagen culture of erbB2-transformed cells
suppressed spreading of cells into collagen (f). B: MT1-MMP mRNA expression is compared among control MDCK cells (–), v-src-transformed cells
(src), erbB2-transformed cells (erbB2) and MDCK cells cultured in type I collagen gel (Gel).
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Fig. 3. Role of membrane type matrix metalloproteinases-1 (MT1-MMP) in cell migration. a, Schematic representation of extra-cellular signal-
regulated kinase (ERK) and MT1-MMP induction on type I collagen. Note that MT1-MMP functions in a positive feedback loop to induce sustained
ERK activation and subsequent MT1-MMP accumulation, which collectively promotes cell migration on collagen b, MMP inhibitor BB94 suppresses
formation of focal adhesion and actin stress fiber in HT1080 cells cultured on collagen, which results in inhibition of cell migration.
Fig. 4. Degradation of lumican by membrane type matrix metalloproteinases-1 (MT1-MMP) abrogates suppression of tumorigenicity. (a) Control
HT1080 (–) or cells stably transfected with lumican gene (Lum) were cultured with or without BB94, and the supernatants and cell lysates were
examined for the expression of lumican and p21/Waf-1, respectively. b, control HT1080 (–) or HT1080/Lum cells were plated into 0.3% agarose
with or without BB94, and colonies were observed under microscopy 2-weeks after incubation. Note that the accumulation level of lumican
protein correlates with p21/Waf-1 expression level and reversely with colony forming ability in agarose.
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than ECM components have been discovered, such as adherence
molecules, cytokines/growth factors and cell surface receptors
(Fig. 5). While the physiological significance of these activities
of MT1-MMP still remain to be explored, MT1-MMP appears
to be involved in regulation of various events taking place at the
cell–ECM interface. These multifunctions of MT1-MMP may
play important roles in not only the initial step of tumor invasion
but also cell growth in distant organs where ECM environments
are different from that of the original tissue. Although MMP has
been expected to be a molecular target for preventing tumor
metastasis, initial clinical tests of broad-spectrum MMP inhibitors
have been disappointing. The development of novel therapeutic
strategies targeting MMP is expected.
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